Rickey James Paul 4

Accession 0001626199-24-000066

CIK 0001626199other

Filed

May 8, 8:00 PM ET

Accepted

May 9, 9:13 PM ET

Size

25.6 KB

Accession

0001626199-24-000066

Form 4

Period: 2024-05-07

Senior VP and CFO

Transactions

Exercise/Conversion
Common Stock
2024-05-07$7.55/sh+1$8→ 31,201 total
Exercise/Conversion
Common Stock
2024-05-07$13.20/sh+7,055$93,126→ 38,256 total
Exercise/Conversion
Common Stock
2024-05-07$6.51/sh+857$5,579→ 39,113 total
Exercise/Conversion
Common Stock
2024-05-07$11.31/sh+164$1,855→ 39,277 total
Exercise/Conversion
Common Stock
2024-05-07$3.23/sh+18,286$59,064→ 57,563 total
Exercise/Conversion
Common Stock
2024-05-07$5.02/sh+398$1,998→ 57,961 total
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−7,055→ 112,945 total
Exercise: $13.20Exp: 2031-01-04→ Common Stock (7,055 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−1→ 108,999 total
Exercise: $7.55Exp: 2033-01-03→ Common Stock (1 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−857→ 143 total
Exercise: $6.51Exp: 2029-02-05→ Common Stock (857 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−164→ 836 total
Exercise: $11.31Exp: 2028-01-01→ Common Stock (164 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−398→ 137 total
Exercise: $5.02Exp: 2027-04-11→ Common Stock (398 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2024-05-07−18,286→ 1,214 total
Exercise: $3.23Exp: 2030-01-22→ Common Stock (18,286 underlying)

Footnotes (8)

[F1]Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024.
[F2]The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
[F3]One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date.
[F4]Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date.
[F5]100% of the shares underlying the option were fully vested as of February 6, 2023.
[F6]100% of the shares underlying the option were fully vested as of January 2, 2022.
[F7]100% of the shares underlying the option were fully vested as of January 23, 2024.
[F8]100% of shares underlying the option were fully vested as of April 1, 2021.

Documents

1 file

ALPINE IMMUNE SCIENCES, INC.

CIK 0001626199

Entity typeother